NASDAQ:TRIL - Trillium Therapeutics SEC Filings & 10K Form

$0.39
+0.02 (+5.41 %)
(As of 09/16/2019 04:00 PM ET)
Today's Range
$0.37
Now: $0.39
$0.39
50-Day Range
$0.26
MA: $0.33
$0.3901
52-Week Range
$0.24
Now: $0.39
$6.50
Volume171,100 shs
Average Volume639,236 shs
Market Capitalization$10.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.21

SEC Filings

Trillium Therapeutics (NASDAQ:TRIL) SEC Filings

DateFilerForm TypeView
09/05/2019
6:03 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/13/2019
6:06 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/24/2019
6:03 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/02/2019
6:07 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/21/2019
12:00 PM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/13/2019
6:01 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/30/2019
6:01 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/15/2019
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/11/2019
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/08/2019
6:06 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/02/2019
6:14 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/27/2019
4:01 PM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/11/2019
4:04 PM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/11/2019
4:03 PM
Trillium Therapeutics (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
03/08/2019
4:00 PM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/04/2019
3:50 PM
Empery Asset Management, LP (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G
03/04/2019
2:45 PM
Growth Equity Opportunities V, LLC (Filed by)
Trillium Therapeutics (Subject)
Form SC 13D/A
02/25/2019
4:05 PM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/25/2019
4:03 PM
Trillium Therapeutics (Filer)
Form SUPPL
02/22/2019
8:01 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/21/2019
7:37 PM
Trillium Therapeutics (Filer)
Form SUPPL
02/21/2019
3:05 PM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/14/2019
3:03 PM
Cormorant Asset Management, LP (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G/A
02/14/2019
1:39 PM
Matrix Capital Management Company, LP (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G/A
02/12/2019
10:05 AM
MORGAN STANLEY (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G/A
01/10/2019
2:39 PM
AWM Investment Company, Inc. (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G/A
12/21/2018
3:03 PM
MORGAN STANLEY (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G
12/03/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/14/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/28/2018
6:19 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/27/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/12/2018
6:15 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/30/2018
8:31 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
08/08/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2018
9:34 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/18/2018
8:52 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/15/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/14/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/07/2018
6:02 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/05/2018
6:01 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/31/2018
11:15 PM
Trillium Therapeutics (Filer)
Form EFFECT
05/16/2018
4:16 PM
Trillium Therapeutics (Filer)
Form F-3
Registration statement for securities of certain foreign private issuers  
05/11/2018
6:05 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/18/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/12/2018
6:11 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/10/2018
6:12 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/04/2018
4:23 PM
Trillium Therapeutics (Filer)
Form 40-F/A
03/20/2018
6:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/09/2018
6:02 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/09/2018
6:01 AM
Trillium Therapeutics (Filer)
Form 40-F
Registration statement pursuant to Section 12 or annual report pursuant to Section 13(a) or 15(d)
02/09/2018
6:01 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
02/06/2018
3:12 PM
JANUS CAPITAL MANAGEMENT LLC (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G/A
01/17/2018
6:15 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/08/2018
11:15 PM
Trillium Therapeutics (Filer)
Form EFFECT
01/08/2018
2:00 PM
Trillium Therapeutics (Filer)
Form F-10/A
12/15/2017
2:02 PM
Trillium Therapeutics (Subject)
Form F-X
Appointment of agent for service of process and undertaking  
12/15/2017
1:31 PM
Trillium Therapeutics (Filer)
Form F-10
Registration statement for securities of certain Canadian issuers  
12/12/2017
2:55 PM
Trillium Therapeutics (Filer)
Form D
Notice of Exempt Offering of Securities 
12/11/2017
7:00 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/08/2017
12:52 PM
Matrix Capital Management Company, LP (Filed by)
Trillium Therapeutics (Subject)
Form SC 13G
12/05/2017
2:42 PM
Growth Equity Opportunities V, LLC (Filed by)
Trillium Therapeutics (Subject)
Form SC 13D/A
12/04/2017
5:10 AM
Trillium Therapeutics (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
This page was last updated on 9/16/2019 by MarketBeat.com Staff

Featured Article: What is operating income?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel